Skip to content

Supplier News

Plan B label change corrects misconceptions

Plan B label change corrects misconceptions

The Food and Drug Administration-approved label change clarifying Plan B One-Step’s mechanism of action was welcome news for the product and the emergency contraception category, says Tara Evans, marketing director for manufacturer Foundation Consumer Healthcare (FCH).

Yaral Pharma partners with EVERSANA

Yaral Pharma partners with EVERSANA

Yaral Pharma the United States generics subsidiary of IBSA (Institut Biochimique SA) announced its expanding partnership with EVERSANA, a leading provider of commercialization services to the global life sciences industry, as its key commercialization partner to support the expansion of its portfoli

FDA approves the Cyltezo Pen

FDA approves the Cyltezo Pen

RIDGEFIELD, Conn. – Boehringer Ingelheim announced Monday that the U.S. Food and Drug Administration (FDA) has approved the Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-adbm), an FDA-approved Interchangeable biosimilar to Humira (adalimumab).